Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are INELIGIBLE
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies); HIV-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible due to potential drug-drug interactions with PT2385
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy
Known HIV-positive patients on combination antiretroviral therapy.
Human immunodeficiency virus (HIV)-positive and on combination antiretroviral therapy
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
A known history of human immunodeficiency virus (HIV) seropositivity; HIV-positive patients on combination antiretroviral therapy are ineligible
Patients may not have known human immunodeficiency virus (HIV) infection; HIV-positive patients on combination antiretroviral therapy are ineligible
Patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients with active human immunodeficiency virus (HIV) or hepatitis C; (HIV-positive patients on combination antiretroviral therapy or hepatitis C-positive patients on antiviral therapy are ineligible)
Patients with known prior human immunodeficiency virus (HIV)-positive status on combination antiretroviral therapy are ineligible; known prior HIV-positive patients with cluster of differentiation (CD)4+ =< 500/mm^3 are ineligible (HIV testing is not required as part of this study)
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV) positive patients on antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are excluded from the study
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions vemurafenib and cobimetinib
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
COHORT 3: ENDOMETRIAL CANCER: HIV-positive patients on combination antiretroviral therapy are ineligible
Patients with human immunodeficiency virus (HIV) on antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive test on combination antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with meclizine.
Human deficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV) seropositive patients with acceptable organ function who meet the patient selection criteria, and who are not on combination antiretroviral therapy, and whose absolute CD4+ count is >= 400 cells per cubic millimeter of blood, will be eligible; however, HIV positive patients on combination antiretroviral therapy will be ineligible, because of the potential for pharmacokinetic interactions with cabozantinib
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy
Patients with known human immunodeficiency virus (HIV) on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV) positive patients with CD4 counts below 500 OR who are not on a stable dose of antiretroviral therapy (for at least 1 month prior to registration) are ineligible
Known human immunodeficiency virus (HIV)-positive patients who are on combination antiretroviral therapy; (this is because of the potential for pharmacokinetic interactions with denosumab)
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible provided they have stable CD4 counts above 250
Patients on combination antiretroviral therapy, i.e. those who are human immunodeficiency virus (HIV)-positive, are ineligible; HIV testing is not required, but patients must not be known to be HIV-positive
Patients who are human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients with uncontrolled HIV despite combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients on combination antiretroviral therapy for the treatment of human immunodeficiency virus (HIV) are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy
PHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
mCRPC EXPANSION COHORT: HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients who are known to be human immunodeficiency positive (HIV)-positive and are on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with vandetanib/metformin
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Subjects known to be human immunodeficiency virus (HIV)-positive, including those on combination antiretroviral therapy, are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients with a known human immunodeficiency virus (HIV)-positive test on combination antiretroviral therapy are ineligible for the initial first-in-man trial
The subject is known to be positive for the human immunodeficiency virus (HIV) and is receiving antiretroviral therapies; subjects known to be HIV-positive who do not require antiretroviral therapy will be eligible if they meet other entry criteria
HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients known to be human immunodeficiency virus (HIV)-positive patients and on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral treatment are ineligible
History of human immunodeficiency virus (HIV) or HIV-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy are ineligible because of unknown potential for interactions with cenersen.
Human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with lenvatinib
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
TUMOR BIOPSY SEQUENCING: Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
TREATMENT: HIV-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV); HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency (HIV)-positive participants on combination antiretroviral therapy are ineligible
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies); HIV-positive participants on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV) or other history of immunodeficiency disorder; HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV) or other history of immunodeficiency disorder \r\n* NOTE: HIV-positive patients taking combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are excluded from the study
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are not eligible
Human immunodeficiency virus (HIV) positive patients who are on combination antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible; unless the patient’s CD4 count is below the institutional lower limit of normal
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible
Subjects known to be human immunodeficiency virus (HIV)-positive, including those on combination antiretroviral therapy, are ineligible
Patients who are human immunodeficiency virus (HIV) positive must be willing to comply with effective antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
HIV-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on CYP3A4 modulating antiretroviral therapy are ineligible
Patients on combination antiretroviral therapy, i.e. those who are human immunodeficiency virus (HIV)-positive, are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; this applies only to patients who have a documented history of HIV and HIV testing is not otherwise required
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Confirmed human immunodeficiency virus (HIV) positive whether or not on antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients on combination antiretroviral therapy, i.e. those who are human immunodeficiency virus (HIV)-positive, are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; Note: patients not on antiretroviral therapies are eligible for this study
Human immunodeficiency virus (HIV)-positive patients or those on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; HIV- positive patients who are not on combination antiretroviral therapy (cART) and have CD4 counts > 500 are eligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patients with human immunodeficiency virus (HIV) whom are not receiving antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible; HIV testing is not required for study enrollment and optional
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy; NOTE: HIV-positive patients on combination antiretroviral therapy are ineligible; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
Patients that are human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy
Patient is human immunodeficiency virus (HIV)-positive and is receiving combination antiretroviral therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy.
HIV-positive patients on combination antiretroviral therapy are ineligible
Subjects who are human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Known human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; this applies only to patients who have a documented history of HIV; HIV testing is not otherwise required
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapies
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy
Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible